You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD30-expression

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

A Study of Chinese Adults With Lymphoma

Recruiting
  • Lymphoma
    • Beijing, Beijing, China
    • +18 more
    Nov 3, 2022

    Peripheral T-cell Lymphoma Trial in Worldwide (brentuximab vedotin, cyclophosphamide, doxorubicin)

    Recruiting
    • Peripheral T-cell Lymphoma
    • brentuximab vedotin
    • +3 more
    • Birmingham, Alabama
    • +45 more
    Jan 4, 2023

    Hodgkin Lymphoma, Adult, T Cell Lymphoma Trial in Barcelona (HSP-CAR30)

    Recruiting
    • Hodgkin Lymphoma, Adult
    • T Cell Lymphoma
    • HSP-CAR30
    • Barcelona, Spain
      Hospital Santa Creu i Sant Pau
    Nov 30, 2020

    Pterygium Trial in Balikesir (Expression of CD44, E-cadherin and PCNA)

    Not yet recruiting
    • Pterygium
    • Expression of CD44, E-cadherin and PCNA
    • Balıkesir, Turkey
      Hümeyra Yildirim
    Sep 15, 2023

    Hodgkin Lymphoma, Relapse, Refractory Trial in Chapel Hill (Chemotherapy, Cell infusion)

    Not yet recruiting
    • Hodgkin Lymphoma
    • +2 more
    • Chapel Hill, North Carolina
      Lineberger Comprehensive Cancer Center
    Oct 13, 2023

    Germ Cell Tumor, Nonseminomatous Germ Cell Tumor Trial in Chapel Hill (ATLCAR.CD30 Cells, Cyclophosphamid, Fludarabine)

    Recruiting
    • Germ Cell Tumor
    • Nonseminomatous Germ Cell Tumor
    • ATLCAR.CD30 Cells
    • +2 more
    • Chapel Hill, North Carolina
      Lineberger Comprehensive Cancer Center at University of North Ca
    Dec 13, 2022

    Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed

    Not yet recruiting
    • Pediatric Cancer
    • +11 more
    • anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
    • Milwaukee, Wisconsin
      Children's Wisconsin
    Sep 14, 2022

    Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases Trial in Chapel Hill (ATLCAR.CD30 cells)

    Recruiting
    • Lymphoma
    • +7 more
    • ATLCAR.CD30 cells
    • Chapel Hill, North Carolina
      Lineberger Comprehensive Cancer Center at University of North Ca
    Dec 2, 2022

    Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma Trial (GEN3017)

    Not yet recruiting
    • Classical Hodgkin Lymphoma
    • Non-Hodgkin Lymphoma
    • GEN3017
    • (no location specified)
    Aug 25, 2023

    Acute Myeloid Leukemia Patients on Correlation to CD200 and CD56

    Not yet recruiting
    • Acute Myeloid Leukemia
    • bone marrow aspirate and biopsy
    • (no location specified)
    Aug 20, 2022

    Acute Myeloid Leukemia Trial in Ramat Gan (CAR-T CD19)

    Recruiting
    • Acute Myeloid Leukemia
    • CAR-T CD19
    • Ramat Gan, Israel
      Chaim Sheba Medical Center
    Oct 30, 2022

    CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma Trial in Houston (Brentuximab Vedotin, Laboratory Biomarker

    Recruiting
    • CD30-Positive Neoplastic Cells Present
    • Malignant Mesothelioma
    • Brentuximab Vedotin
    • Laboratory Biomarker Analysis
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 3, 2022

    Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma Trial in Duarte, Nashville, Houston

    Active, not recruiting
    • Anaplastic Large Cell Lymphoma
    • +4 more
    • Duarte, California
    • +3 more
    Jul 21, 2022

    Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma Trial in Houston (CD30.CAR-EBVST cells)

    Recruiting
    • Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
    • Classical Hodgkin Lymphoma
    • CD30.CAR-EBVST cells
    • Houston, Texas
    • +1 more
    Jul 20, 2022

    Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Seattle (drug, other,

    Recruiting
    • Recurrent Hodgkin Lymphoma
    • +3 more
    • Brentuximab Vedotin
    • +2 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Oct 4, 2022

    Immune Markers in Pediatric ITP

    Not yet recruiting
    • ITP - Immune Thrombocytopenia
    • complete blood count, CD3+ , CD4+ , CD8+, CD16+, CD56+, IFN-γ.
    • (no location specified)
    Oct 17, 2023

    Lymphoma, Relapse/Recurrence Trial in Wuhan, Nanchang (CD30 CAR-T, Camrelizumab)

    Recruiting
    • Lymphoma
    • Relapse/Recurrence
    • Wuhan, Hubei, China
    • +1 more
    Apr 8, 2022

    Immune Thrombocytopenia Trial in Sohag (Genotyping of rs1980422-related single-nucleotide polymorphisms by real time PCR)

    Not yet recruiting
    • Immune Thrombocytopenia
    • Genotyping of rs1980422-related single-nucleotide polymorphisms by real time PCR
    • Sohag, Egypt
      Sohag University Hospital
    Jul 19, 2022

    Recurrent Lymphoproliferative Disorder, Refractory Lymphoproliferative Disorder Trial in Duarte (Leflunomide)

    Active, not recruiting
    • Recurrent Lymphoproliferative Disorder
    • Refractory Lymphoproliferative Disorder
    • Duarte, California
      City of Hope Medical Center
    Jun 7, 2022

    Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma Trial (AFM13, AB-101, Cyclophosphamide)

    Not yet recruiting
    • Relapsed or Refractory Hodgkin Lymphoma
    • Peripheral T Cell Lymphoma
    • (no location specified)
    May 30, 2023

    T Cell Lymphoma Trial in Kansas City (Brentuximab Vedotin)

    Withdrawn
    • T Cell Lymphoma
    • Brentuximab Vedotin
    • Kansas City, Kansas
      The University of Kansas Cancer Center, Westwood Campus
    Feb 1, 2023

    Lymphatic Diseases Trial in Italy (Brentuximab Vedotin)

    Completed
    • Lymphatic Diseases
    • Brentuximab Vedotin
    • Bologna, Italy
    • +3 more
    Mar 21, 2022

    FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid

    Not yet recruiting
    • Acute Myeloid Leukemia
      • (no location specified)
      May 17, 2022

      Hodgkin Lymphoma Trial in Valhalla (Brentuximab Vedotin, Allogeneic Stem Cell Transplantation, Reduced Intensity Conditioning)

      Active, not recruiting
      • Hodgkin Lymphoma
      • Brentuximab Vedotin
      • +2 more
      • Valhalla, New York
        New York Medical College
      Oct 24, 2022

      Lymphoma Trial in China (Brentuximab Vedotin, Cyclophosphamide, Doxorubicin)

      Not yet recruiting
      • Lymphoma
      • Brentuximab Vedotin
      • +3 more
      • Beijing, China
      • +15 more
      Jan 4, 2023